Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
Peking University · Peking University Cancer Hospital · +34 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
192
total citations
- FWCI
- 41.74
- Percentile
- 100%
- References
- 29
Citations per year
Authors
52Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Response Evaluation Criteria in Solid Tumors
- Adverse effect
- Oncology
- Clinical trial
- Antibody
- Phases of clinical research
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.